Entasis Therapeutics Holdings Inc. (ETTX) NASDAQ
$2.19 - (-)
Market Cap: -
As of 07/08/22 12:00 AM EDT. Market closed.
Entasis Therapeutics Holdings Inc. (ETTX)
NASDAQ
$2.19
- (-)
Market Cap: -
As of 07/08/22 12:00 AM EDT. Market closed.
Add to Portfolio
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), ... read more
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). read less
COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Full Time Employees
47
Address
.
PRICE CHART FOR ENTASIS THERAPEUTICS HOLDINGS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
-
Previous Close
$2.19
Days Range
$2.19 - $2.20
52 week range
- - -
Volume
0
Avg. Volume (30 days)
0
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
47,851,779
Open
-
Previous Close
$2.19
Days Range
$2.19 - $2.20
52 week range
- - -
Volume
0
Avg. Volume (30 days)
0
Market Cap
-
Dividend Yield
-
P/E
-
Shares Outstanding
47,851,779
FINANCIAL STATEMENTS FOR ENTASIS THERAPEUTICS HOLDINGS INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR ENTASIS THERAPEUTICS HOLDINGS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Innoviva, Inc. | 10% Owner | Jul 11, 2022 | Buy | $2.20 | 7,598,814 | 16,717,391 | 29,270,476 | Jul 13, 2022, 09:27 PM |
| Innoviva, Inc. | 10% Owner | Jul 08, 2022 | Buy | $2.20 | 11,671,662 | 25,677,657 | 21,671,662 | Jul 13, 2022, 09:27 PM |
| Tommasi Ruben | Chief Scientific Officer | Jul 07, 2022 | Option Exercise | $2.20 | 39,596 | 87,111 | 0 | Jul 11, 2022, 04:09 PM |
| Ronsheim Matthew | Chief of Pharma Sciences & MFG | Jul 07, 2022 | Option Exercise | $2.20 | 17,572 | 38,658 | 0 | Jul 11, 2022, 04:09 PM |
| Perros Manoussos | President and CEO | Jul 07, 2022 | Option Exercise | $2.20 | 56,072 | 123,358 | 0 | Jul 11, 2022, 04:08 PM |
| Mueller John Patrick | Chief Development Officer | Jul 07, 2022 | Option Exercise | $2.20 | 17,092 | 37,602 | 0 | Jul 11, 2022, 04:07 PM |
| Meek David D. | Director | Jul 11, 2022 | Option Exercise | $2.20 | 27,500 | 60,500 | 0 | Jul 11, 2022, 04:07 PM |
| Meek David D. | Director | Jul 07, 2022 | Option Exercise | $2.20 | 22,000 | 48,400 | 0 | Jul 11, 2022, 04:07 PM |
| Mayer Howard | Director | Jul 11, 2022 | Option Exercise | $2.20 | 27,500 | 60,500 | 0 | Jul 11, 2022, 04:06 PM |
| Mayer Howard | Director | Jul 07, 2022 | Option Exercise | $2.20 | 22,000 | 48,400 | 0 | Jul 11, 2022, 04:06 PM |
| Keiley Elizabeth M | General Counsel | Jul 07, 2022 | Option Exercise | $2.20 | 17,572 | 38,658 | 0 | Jul 11, 2022, 04:06 PM |
| HASTINGS DAVID C | Director | Jul 11, 2022 | Option Exercise | $2.20 | 27,500 | 60,500 | 0 | Jul 11, 2022, 04:05 PM |
| HASTINGS DAVID C | Director | Jul 07, 2022 | Option Exercise | $2.20 | 22,000 | 48,400 | 0 | Jul 11, 2022, 04:05 PM |
| Berger Heather A. | Director | Jul 11, 2022 | Option Exercise | $2.20 | 27,500 | 60,500 | 0 | Jul 11, 2022, 04:04 PM |
| Berger Heather A. | Director | Jul 07, 2022 | Option Exercise | $2.20 | 22,000 | 48,400 | 0 | Jul 11, 2022, 04:04 PM |
| Altarac David | Chief Medical Officer | Jul 07, 2022 | Option Exercise | $2.20 | 17,572 | 38,658 | 0 | Jul 11, 2022, 04:03 PM |
| Ronsheim Matthew | Chief, Pharma Sciences & MFG. | Nov 02, 2021 | Option Exercise | $2.94 | 3,669 | 10,787 | 42,572 | Nov 03, 2021, 04:05 PM |
| Keiley Elizabeth M | General Counsel | Nov 02, 2021 | Option Exercise | $2.94 | 3,669 | 10,787 | 42,572 | Nov 03, 2021, 04:04 PM |
| Altarac David | Chief Medical Officer | Nov 02, 2021 | Option Exercise | $2.94 | 3,669 | 10,787 | 42,572 | Nov 03, 2021, 04:04 PM |
| Mueller John Patrick | Chief Development Officer | Nov 02, 2021 | Option Exercise | $2.94 | 3,907 | 11,487 | 42,092 | Nov 03, 2021, 04:03 PM |
| Perros Manoussos | President and CEO | Nov 02, 2021 | Option Exercise | $2.94 | 11,704 | 34,410 | 135,822 | Nov 03, 2021, 04:03 PM |
| Gutch Michael | CFO and Chief Business Officer | Nov 02, 2021 | Option Exercise | $2.94 | 3,669 | 10,787 | 42,572 | Nov 03, 2021, 04:02 PM |
| Tommasi Ruben | Chief Scientific Officer | Nov 02, 2021 | Option Exercise | $2.94 | 3,669 | 10,787 | 64,596 | Nov 03, 2021, 04:02 PM |
| Perros Manoussos | See Remarks | Oct 19, 2021 | Sale | $3.19 | 11,974 | 38,197 | 147,526 | Oct 20, 2021, 04:14 PM |
| Mueller John Patrick | Chief Development Officer | Oct 19, 2021 | Sale | $3.19 | 4,001 | 12,763 | 45,999 | Oct 20, 2021, 04:10 PM |
| Gutch Michael | See Remarks | Oct 19, 2021 | Sale | $3.19 | 3,759 | 11,991 | 46,241 | Oct 20, 2021, 04:09 PM |
| Tommasi Ruben | Chief Scientific Officer | Oct 19, 2021 | Sale | $3.19 | 3,759 | 11,991 | 68,265 | Oct 20, 2021, 04:08 PM |
| Keiley Elizabeth M | General Counsel | Oct 19, 2021 | Sale | $3.19 | 3,759 | 11,991 | 46,241 | Oct 20, 2021, 04:08 PM |
| Altarac David | Chief Medical Officer | Oct 19, 2021 | Sale | $3.19 | 3,759 | 11,991 | 46,241 | Oct 20, 2021, 04:06 PM |
| Ronsheim Matthew | See Remarks | Oct 19, 2021 | Sale | $3.19 | 3,759 | 11,991 | 46,241 | Oct 20, 2021, 04:05 PM |
| Innoviva, Inc. | 10% Owner | Sep 01, 2020 | Buy | $2.67 | 4,672,897 | 12,499,999 | 18,672,897 | Sep 01, 2020, 05:31 PM |
| Innoviva, Inc. | 10% Owner | Jun 11, 2020 | Buy | $2.50 | 12,677,490 | 31,693,725 | 14,000,000 | Jun 12, 2020, 05:34 PM |
| Frazier Life Sciences VIII, L.P. | 10% Owner | Jan 09, 2020 | Sale | $5.00 | 50,000 | 250,010 | 1,299,953 | Jan 13, 2020, 10:47 AM |
| Tommasi Ruben | Chief Scientific Officer | Dec 21, 2018 | Option Exercise | $3.45 | 22,024 | 75,921 | 22,024 | Dec 26, 2018, 04:45 PM |
| Topper James N | Director | Sep 28, 2018 | Buy | $15.00 | 375,887 | 5,638,305 | 1,349,953 | Oct 02, 2018, 09:42 PM |
| Sofinnova Venture Partners IX, L.P. | 10% Owner | Sep 28, 2018 | Buy | $15.00 | 337,724 | 5,065,860 | 1,180,178 | Oct 02, 2018, 09:41 PM |
| Preston Heather | Director | Sep 28, 2018 | Buy | $15.00 | 337,724 | 5,065,860 | 1,180,178 | Oct 02, 2018, 09:40 PM |
| Pivotal bioVenture Partners Fund I, L.P. | 10% Owner | Sep 28, 2018 | Buy | $15.00 | 337,724 | 5,065,860 | 1,180,178 | Oct 02, 2018, 09:39 PM |
| GALAKATOS NICHOLAS | Director | Sep 28, 2018 | Buy | $15.00 | 453,395 | 6,800,925 | 1,623,405 | Oct 02, 2018, 09:38 PM |
| Frazier Life Sciences VIII, L.P. | 10% Owner | Sep 28, 2018 | Buy | $15.00 | 375,887 | 5,638,305 | 1,349,953 | Oct 02, 2018, 09:38 PM |
| Clarus Lifesciences III, L.P. | 10% Owner | Sep 28, 2018 | Buy | $15.00 | 453,395 | 6,800,925 | 1,623,405 | Oct 02, 2018, 09:36 PM |
| ASTRAZENECA PLC | 10% Owner | Sep 28, 2018 | Buy | $15.00 | 246,666 | 3,699,990 | 2,164,855 | Oct 02, 2018, 09:35 PM |
| TPG Group Holdings (SBS) Advisors, Inc. | Former 10% Owner | Sep 28, 2018 | Buy | $15.00 | 262,539 | 3,938,085 | 1,020,748 | Oct 02, 2018, 04:46 PM |
| Novo Holdings A/S | 10% Owner | Sep 28, 2018 | Buy | $15.00 | 1,089,835 | 16,347,525 | 2,181,843 | Oct 01, 2018, 04:36 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Innoviva, Inc. | 10% Owner | 07/11/2022 | 16,717,391 |
| Innoviva, Inc. | 10% Owner | 07/08/2022 | 25,677,657 |
| Tommasi Ruben | Chief Scientific Officer | 07/07/2022 | 87,111 |
| Ronsheim Matthew | Chief of Pharma Sciences & MFG | 07/07/2022 | 38,658 |
| Perros Manoussos | President and CEO | 07/07/2022 | 123,358 |
| Mueller John Patrick | Chief Development Officer | 07/07/2022 | 37,602 |
| Meek David D. | Director | 07/11/2022 | 60,500 |
| Meek David D. | Director | 07/07/2022 | 48,400 |
| Mayer Howard | Director | 07/11/2022 | 60,500 |
| Mayer Howard | Director | 07/07/2022 | 48,400 |
| Keiley Elizabeth M | General Counsel | 07/07/2022 | 38,658 |
| HASTINGS DAVID C | Director | 07/11/2022 | 60,500 |
| HASTINGS DAVID C | Director | 07/07/2022 | 48,400 |
| Berger Heather A. | Director | 07/11/2022 | 60,500 |
| Berger Heather A. | Director | 07/07/2022 | 48,400 |
| Altarac David | Chief Medical Officer | 07/07/2022 | 38,658 |
| Ronsheim Matthew | Chief, Pharma Sciences & MFG. | 11/02/2021 | 10,787 |
| Keiley Elizabeth M | General Counsel | 11/02/2021 | 10,787 |
| Altarac David | Chief Medical Officer | 11/02/2021 | 10,787 |
| Mueller John Patrick | Chief Development Officer | 11/02/2021 | 11,487 |
| Perros Manoussos | President and CEO | 11/02/2021 | 34,410 |
| Gutch Michael | CFO and Chief Business Officer | 11/02/2021 | 10,787 |
| Tommasi Ruben | Chief Scientific Officer | 11/02/2021 | 10,787 |
| Perros Manoussos | See Remarks | 10/19/2021 | 38,197 |
| Mueller John Patrick | Chief Development Officer | 10/19/2021 | 12,763 |
| Gutch Michael | See Remarks | 10/19/2021 | 11,991 |
| Tommasi Ruben | Chief Scientific Officer | 10/19/2021 | 11,991 |
| Keiley Elizabeth M | General Counsel | 10/19/2021 | 11,991 |
| Altarac David | Chief Medical Officer | 10/19/2021 | 11,991 |
| Ronsheim Matthew | See Remarks | 10/19/2021 | 11,991 |
| Innoviva, Inc. | 10% Owner | 09/01/2020 | 12,499,999 |
| Innoviva, Inc. | 10% Owner | 06/11/2020 | 31,693,725 |
| Frazier Life Sciences VIII, L.P. | 10% Owner | 01/09/2020 | 250,010 |
| Tommasi Ruben | Chief Scientific Officer | 12/21/2018 | 75,921 |
| Topper James N | Director | 09/28/2018 | 5,638,305 |
| Sofinnova Venture Partners IX, L.P. | 10% Owner | 09/28/2018 | 5,065,860 |
| Preston Heather | Director | 09/28/2018 | 5,065,860 |
| Pivotal bioVenture Partners Fund I, L.P. | 10% Owner | 09/28/2018 | 5,065,860 |
| GALAKATOS NICHOLAS | Director | 09/28/2018 | 6,800,925 |
| Frazier Life Sciences VIII, L.P. | 10% Owner | 09/28/2018 | 5,638,305 |
| Clarus Lifesciences III, L.P. | 10% Owner | 09/28/2018 | 6,800,925 |
| ASTRAZENECA PLC | 10% Owner | 09/28/2018 | 3,699,990 |
| TPG Group Holdings (SBS) Advisors, Inc. | Former 10% Owner | 09/28/2018 | 3,938,085 |
| Novo Holdings A/S | 10% Owner | 09/28/2018 | 16,347,525 |
Load More Insider Transactions
BUYBACK ANNOUNCEMENT(S) FOR ENTASIS THERAPEUTICS HOLDINGS INC
LOADING...